[2nd European Breast Cancer Conference, Bruxelles, September 26-30,  2000. Interview with Anthony Howell].
Howell
A
A
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen; D017273:Goserelin